Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Trump Reportedly Approves Plan to Remove FDA Commissioner Marty Makary Amid Growing Controversies 
The four types of dementia most people don’t know exist 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
